NFE2L3 Antibodies

Nuclear factor erythroid 2-related factor 3 (NFE2L3)

Activates erythroid-specific, globin gene expression. .

Gene Information

Human
Gene Name:	NFE2L3
Uniprot:	Q9Y4A8
Entrez:	9603

Family

Belongs to:
bZIP family

Alternative Names

NF-E2-related factor 3; NFE2-related factor 3; Nrf3; NRF3nuclear factor erythroid 2-related factor 3; nuclear factor (erythroid-derived 2)-like 3; Nuclear factor, erythroid derived 2, like 3; nuclear factor-erythroid 2 p45-related factor 3; nuclear factor-erythroid 2-related factor 3

Molecular Weight

Mass (kDA):
76.154 kDA

Genomic Context

Human
Location:	7p15.2
Sequence:	7; NC_000007.14 (26152198..26187137)

Tissue Specificity

Highly expressed in human placenta and also in B-cell and monocyte cell lines. Low expression in heart, brain, lung, skeletal muscle, kidney and pancreas.

Subcellular Localizations

Nucleus.

Diseases

• Carcinogenesis
• Neoplasms
• Malignant Neoplasms
• Inflammation
• Skin Wound
• Adenoma
• Hematopoietic Neoplasms
• Endometrial Polyp
• Placental Choriocarcinoma
• Endometriosis, Site Unspecified
• Tumor Angiogenesis
• Trophoblastic Neoplasms

• Pain
• Lymphoma
• Colorectal Cancer
• Adenocarcinoma
• Cell Transformation, Neoplastic
• Leukemogenesis

Interacting Proteins

• MAFG
• NFE2

Pathways

• Localization
• Decidualization
• Glycosylation
• Angiogenesis
• Wound Healing
• Rna Interference
• Conjugation

• Oncogenesis

PTMs

• Glycosylation

• Ubiquitination

Research Areas

• Stem Cell Markers

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/NFE2L3

Anti-Nrf3 NFE2L3 Marker From Boster Bio

Boster Bio's Anti-Nrf3 NFE2L3 marker provides high-affinity primary antibodies that can be used in cancer research. This antibody is available for use with different types of cell types. Here are some examples of its use. Continue reading to learn more. NFE2L3 can be detected in many cell types

Boster Bio Anti-Nrf3 NFE2L3 Marker

Boster Bio Anti-Nrf3-NFE2L3Marker, a polyclonal antibodies that detects the expression this gene, is available. This product has several potential applications. The protein is highly specific for NFE2L3+ cells. It is recommended to researchers who are searching for a particular protein in a cell-culture sample. Based on the results, it should be decided by the researcher which method is best.

Boster offers high-affinity primary antibodies

The F-box protein is a family of proteins that contain the C-terminal Nictaba-like domain. The F-box protein specifically targets poly-N-acetyllactosamine, blood type B motifs, and Lewis A and X motifs. These proteins are found in tissues and cells as well as the brain. The F-box proteins play a critical role in the regulation and metabolism of cells.

NFE2L3 Detection in a Variety of Cell Types

Detection of NFE2L3, a member of the NF-E2 family, is a common molecular target for transcription factors. This protein is a regulator of the antioxidant response. Its role in regulating gene transcription has been linked to many biological processes including placental formation and solid tumor formation in stem cell cells. NFE2L3 expression has been associated with the diagnosis of colorectal or testicular seminoma. It has been discovered that NFE2L3 expression increases in hematopoietic and hematopoietic types of cancers such as colon, breast, colon, and colon.

The detection of NFE2L3 in various cell types was made possible through the development of a specific antibody. The recombinant CTHRC1 antibody was tested using a DAS ELISA. The antigen was detected in leukocytes as well as colon cancer cell lines HT29/SW620. The antibody recognizes both native as recombinant forms.

PCR was used for amplifying a truncated NFE2L3 using an expression vector. The total RNA of HCT116 cell was reverse-transcribed. Two oligonucleotides that target NFE2L3 were also created. Amplification was carried out in a volume of 50 ml, and involved 35 cycles at 94degC for 30 seconds and a final extension step at 72degC for 10 minutes.

While studies on NFE2L3 have focused on its mRNA and protein levels, it has also been identified as a potential biomarker in tumors. Expression of NFE2L3 in various cell types has been shown to affect tumor progression and response to immunocheckpoint inhibitors. It has also been found to modulate immune system function, including T cell exhaustion, which is a hallmark of hot tumors. It may therefore be useful in predicting the response of immune checkpoint inhibitor medications.

Chessboard titrations utilizing the sFabE5/PAb were used to determine optimal anti-NFE2L3 concentrations. The optimal concentrations of the anti-NFE2L3 antibody were 0.6 mg/well in CH21D7, 0.5 mg/well in E5 and 1:140000 in CH24D7. Furthermore, the optimal washing conditions and incubation time were determined by reagent titration experiments. Anti-NFE2L3 reagents did not affect the CTHRC1 readings.

Application in cancer-research

A new tool called aptamers could revolutionize cancer research. These nucleic acid binding ligands are created through molecular evolution and have high affinity for target molecules. In particular, aptamer-based applications span cancer targeting, biomarker discovery, and therapeutics. Avamer-conjugated nanocarriers promise lower toxicity.

Multi-OMICS approaches are especially well-suited to bridge the gap between phenotypic as well as genotype-driven characteristics of cancers. These methods can help identify the role of TF driven transcription regulatory networks. The next steps for the OMICS field are to increase reproducibility and speed up sample processing. They are able detect cancer-specific mutations in patients and predict their treatment outcomes. Scientists must answer fundamental questions in order to harness the full potential of OMICS-based research.

A lack of adequate sample preparation is a major problem faced by cancer researchers. To study the morphology of cancer cells and their mechanical properties, researchers must first isolate cancer-causing cells and then characterize them. Researchers must collect tissues from many locations to accomplish this. This is possible through AFM-based Microscopy. Cancer cells can sometimes be difficult to find in tissues so researchers need to use multiple methods to study them. If the cancer cells can not be analyzed using atomic force microscopic, they should be removed.

Biomarkers are changes in the molecular sequence, expression, structure, or function a cell. These mutations enable cancer cells to acquire certain characteristics that allow them to survive cell death and support proliferation. The cancer biomarkers identified by these techniques play a key role in detecting and monitoring the progression of the disease. Researchers can identify biomarkers from cancer samples and develop more effective treatments.

The Cancer Prevention and Research Institute of Texas supports the new DSICCR research initiative. This initiative will make cutting-edge information technology and data science research accessible to everyone. The center will also provide data science services to all levels of cancer researchers, as well as infrastructure for "big data" in order to support their research. And finally, the DSICCR will create a data science education for cancer researchers.